Trial Profile
Pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2011
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Biomarker; Therapeutic Use
- 28 Jul 2011 New trial record